L1 HAS NO ANSWERS
L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 9 3
NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE

=> s l1 ful
FULL SEARCH INITIATED 08:31:57 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 17390 TO ITERATE

100.0% PROCESSED 17390 ITERATIONS 100 ANSWERS
SEARCH TIME: 00.00.01

L3 100 SEA SSS FUL L1

AN 2003:818416 CAPLUS
DN 139:323436
TI Preparation of pyridinoylpiperidines as 5-HT1F agonists
IN Cohen, Michael Philip; Kohlman, Daniel Timothy; Liang, Sidney Xi; Mancuso, Vincent; Victor, Frantz; Xu, Yao-Chang; Ying, Bai-Ping; Zacherl, Deanna Piatt; Zhang, Deyi
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003084949	A1	20031016	WO 2003-US8455	20030327
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	TW 263497	B	20061011	TW 2003-92106334	20030321
	NZ 534952	A	20051125	NZ 2003-534952	20030324
	CA 2478229	A1	20031016	CA 2003-2478229	20030327
	AU 2003224719	A1	20031020	AU 2003-224719	20030327
	EP 1492786	A1	20050105	EP 2003-721402	20030327
	EP 1492786	B1	20061004		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003008495	A	20050201	BR 2003-8495	20030327
	CN 1642939	A	20050720	CN 2003-807363	20030327
	JP 2005530722	T	20051013	JP 2003-582146	20030327
	AT 341543	T	20061015	AT 2003-721402	20030327
	ZA 2004007666	A	20060222	ZA 2004-7666	20040922
	US 2005222206	A1	20051006	US 2004-509770	20040928
	NO 2004004654	A	20041028	NO 2004-4654	20041028
	HK 1073464	A1	20070504	HK 2005-104936	20050613
PRAI	US 2002-369088P	P	20020329		
	WO 2003-US8455	W	20030327		

OS CASREACT 139:323436; MARPAT 139:323436
GI



I

AB Title compds. [I; R1 = (substituted) alkyl, cycloalkyl, cycloalkylalkyl, Ph, heterocycle; R2 = H, alkyl, cycloalkylalkyl, pyrazolylalkyl; R3 = H, alkyl; R4 = H, halo, alkyl; R5 = H, alkyl], were prepared for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the

treatment or prevention of migraine. Thus, 2-amino-6-(1-methylpiperidin-4-ylcarbonyl)pyridine (preparation given), 4-fluorobenzoyl chloride, and Et3N were stirred in CH2Cl2 at room temperature for 4 h to give 4-fluoro-N-[6-(1-methylpiperidin-4-ylcarbonyl)pyridin-2-yl]benzamide dihydrochloride. I bound to as 5-HT1F receptors with Ki <300 nM. I drug formulations are given.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d scan l21

L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, 5-bromo-2-methoxy-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]- (9CI)
MF C20 H22 Br N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):15

L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, 4-fluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]-2-(trifluoromethyl)-, monohydrochloride (9CI)
MF C20 H19 F4 N3 O2 . Cl H



● HCl

L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 7-Benzofurancarboxylic acid, 2,3-dihydro-
MF C9 H8 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Propanal
MF C3 H6 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, 2-methoxy-6-methyl-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]- (9CI)
MF C21 H25 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Indole-3-carboxamide, N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]- (9CI)

MF C21 H22 N4 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzoic acid, 2-methoxy-4-(methylthio)-
MF C9 H10 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 3-Furancarboxylic acid
MF C5 H4 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Benzamide, 2,6-difluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]- (9CI)
MF C19 H19 F2 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-ethyl-2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]- (9CI)
MF C21 H22 F3 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]- (9CI)
MF C13 H12 N2 O5
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,4-Benzenedicarboxylic acid, 1-methyl ester
MF C9 H8 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, 2-fluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]-4-(trifluoromethyl)- (9CI)
MF C20 H19 F4 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 3-Furancarboxamide, N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]-(9CI)
MF C17 H19 N3 O3


O
C
O
NH
N
N
Me
C
O

```
=> d l4
L4 HAS NO ANSWERS
L4                STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   9   3
NUMBER OF NODES IS  15

STEREO ATTRIBUTES: NONE


=> search l4
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:l3
'L3' IS NOT A VALID SEARCH SCOPE
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:subset
ENTER SUBSET L# OR (END):l3
ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful
FULL SUBSET SEARCH INITIATED 08:32:27 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -       12 TO ITERATE

100.0% PROCESSED       12 ITERATIONS                              11 ANSWERS
SEARCH TIME: 00.00.01

L5            11 SEA SUB=L3 SSS FUL L4
```

```
=> s l5
L6            2 L5

=> d bib abs 1-2

L6   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2003:818416  CAPLUS
DN   139:323436
TI   Preparation of pyridinoylpiperidines as 5-HT1F agonists
IN   Cohen, Michael Philip; Kohlman, Daniel Timothy; Liang, Sidney Xi; Mancuso,
     Vincent; Victor, Frantz; Xu, Yao-Chang; Ying, Bai-Ping; Zacherl, Deanna
     Piatt; Zhang, Deyi
PA   Eli Lilly and Company, USA
SO   PCT Int. Appl., 90 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
PI   WO 2003084949         A1    20031016    WO 2003-US8455           20030327
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     TW 263497             B     20061011    TW 2003-92106334         20030321
     NZ 534952             A     20051125    NZ 2003-534952           20030324
     CA 2478229            A1    20031016    CA 2003-2478229          20030327
     AU 2003224719         A1    20031020    AU 2003-224719           20030327
     EP 1492786            A1    20050105    EP 2003-721402           20030327
     EP 1492786            B1    20061004
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     BR 2003008495         A     20050201    BR 2003-8495             20030327
     CN 1642939            A     20050720    CN 2003-807363           20030327
     JP 2005530722         T     20051013    JP 2003-582146           20030327
     AT 341543             T     20061015    AT 2003-721402           20030327
     ZA 2004007666         A     20060222    ZA 2004-7666             20040922
     US 2005222206         A1    20051006    US 2004-509770           20040928
     NO 2004004654         A     20041028    NO 2004-4654             20041028
     HK 1073464            A1    20070504    HK 2005-104936           20050613
PRAI US 2002-369088P       P     20020329
     WO 2003-US8455        W     20030327
OS   CASREACT 139:323436; MARPAT 139:323436
GI
```



I

AB Title compds. [I; R1 = (substituted) alkyl, cycloalkyl, cycloalkylalkyl, Ph, heterocycle; R2 = H, alkyl, cycloalkylalkyl, pyrazolylalkyl; R3 = H, alkyl; R4 = H, halo, alkyl; R5 = H, alkyl], were prepared for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine. Thus, 2-amino-6-(1-methylpiperidin-4-ylcarbonyl)pyridine (preparation given), 4-fluorobenzoyl chloride, and Et3N were stirred in CH2Cl2 at room temperature for 4 h to give 4-fluoro-N-[6-(1-methylpiperidin-4-ylcarbonyl)pyridin-2-yl]benzamide dihydrochloride. I bound to as 5-HT1F receptors with Ki <300 nM. I drug formulations are given.
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:218963 CAPLUS
DN 130:352171
TI Synthesis and antinociceptive activity of some 3-chlorophenyl- and 6-chloro-2-pyridinyl derivatives
AU Radl, Stanislav; Hafner, Wieland; Hezky, Petr; Krejci, Ivan; Proska, Jan; Hajicek, Josef
CS Research Institute of Pharmacy and Biochemistry, Prague, 13060/3, Czech Rep.
SO Collection of Czechoslovak Chemical Communications (1999), 64(2), 377-388
CODEN: CCCCAK; ISSN: 0010-0765
PB Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic
DT Journal
LA English
AB Derivs. of 2-chloro-6-(4-hydroxy-1-methyl-4-piperidinyl)pyridine were prepared and tested as analgesics. 2-Chloro-6-lithiopyridine treated with 3-quinuclidinone, 1-methyl-3-pyrrolidinone, 2-(dimethylaminomethyl)cyclohexanone, and Et 1-methyl-4-piperidinylcarboxylate provided the corresponding alcs. A ketone was reduced with sodium borohydride or treated with methylmagnesium chloride or phenyllithium to provide the corresponding alcs. 1-[4-(6-Chloro-2-pyridyl)-1-methyl-4-piperidinyl]-1-methylethanol was prepared from 2-chloro-6-(1-methyl-1,2,5,6-tetrahydro-4-pyridinyl)pyridine by treatment with butyllithium and acetone followed by reduction of an intermediate with sodium cyanoborohydride.
RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitstr 2

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:218963 CAPLUS
DN 130:352171
TI Synthesis and antinociceptive activity of some 3-chlorophenyl- and 6-chloro-2-pyridinyl derivatives
AU Radl, Stanislav; Hafner, Wieland; Hezky, Petr; Krejci, Ivan; Proska, Jan; Hajicek, Josef
CS Research Institute of Pharmacy and Biochemistry, Prague, 13060/3, Czech Rep.
SO Collection of Czechoslovak Chemical Communications (1999), 64(2), 377-388
CODEN: CCCCAK; ISSN: 0010-0765
PB Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic
DT Journal
LA English
AB Derivs. of 2-chloro-6-(4-hydroxy-1-methyl-4-piperidinyl)pyridine were prepared and tested as analgesics. 2-Chloro-6-lithiopyridine treated with 3-quinuclidinone, 1-methyl-3-pyrrolidinone, 2-(dimethylaminomethyl)cyclohexanone, and Et 1-methyl-4-

piperidinylcarboxylate provided the corresponding alcs. A ketone was reduced with sodium borohydride or treated with methylmagnesium chloride or phenyllithium to provide the corresponding alcs. 1-[4-(6-Chloro-2-pyridyl)-1-methyl-4-piperidinyl]-1-methylethanol was prepared from 2-chloro-6-(1-methyl-1,2,5,6-tetrahydro-4-pyridinyl)pyridine by treatment with butyllithium and acetone followed by reduction of an intermediate with sodium cyanoborohydride.

IT 225112-39-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and analgesic activity of (piperidinyl)pyridinemethanol or (pyridinyl)cyclohexanol or (pyridinyl)piperidinemethanol derivs.)

RN 225112-39-0 CAPLUS

CN 2-Pyridinemethanol, 6-chloro-α-(1-methyl-4-piperidinyl)-α-phenyl-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 225112-26-5
CMF C18 H21 Cl N2 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



IT 225112-16-3P 225112-26-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and analgesic activity of (piperidinyl)pyridinemethanol or (pyridinyl)cyclohexanol or (pyridinyl)piperidinemethanol derivs.)

RN 225112-16-3 CAPLUS

CN Methanone, (6-chloro-2-pyridinyl)(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 225112-26-5 CAPLUS
CN 2-Pyridinemethanol, 6-chloro-α-(1-methyl-4-piperidinyl)-α-phenyl- (9CI) (CA INDEX NAME)



```
=> d his l23-l24

     (FILE 'CAPLUS' ENTERED AT 08:43:31 ON 30 MAY 2007)
L23            7 S L3
L24            5 S L3 NOT L6

=> d bib abs hitstr 1-5

L24  ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2006:766432  CAPLUS
DN   145:195697
TI   Compositions comprising a 5-HTiF-specific agonist and an NSADD and
     therapeutic methods for migraine and headache pain
IN   Plachetka, John R.
PA   Pozen Inc., USA
SO   PCT Int. Appl., 35pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 2006081127         A2    20060803    WO 2006-US1882          20060119
     WO 2006081127         A3    20070308
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
             KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
             MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
             SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
             VN, YU, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
     US 2006178349         A1    20060810    US 2006-332795          20060117
PRAI US 2005-645599P       P     20050124
     US 2006-332795        A     20060117
AB   The present invention is directed to compns. containing a 5-HTiF-specific
     agonist that acts by blocking protein extravasation together with an
     NSADD.  These compns. may be used to treat migraine and headache pain.
     The invention also includes methods in which these drugs are sep.
     administered to a patient.
IT   439239-90-4
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (compns. comprising 5-HTiF-specific agonist and NSADD and therapeutic
        methods for migraine and headache pain)
RN   439239-90-4  CAPLUS
CN   Benzamide, 2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-
     pyridinyl]- (9CI)  (CA INDEX NAME)
```



L24 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:991014 CAPLUS
DN 145:145570
TI A novel method for the synthesis of carbon-14-labeled N-[3-(1-methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]propanamide and its use in quantitative whole-body autoradiography studies
AU Wheeler, William J.; Chay, Sylvia H.; Herman, Jennifer L.; O'Bannon, Douglas D.
CS Lilly Research Laboratories, A Division of Eli Lilly and Company, Indianapolis, IN, 46285, USA
SO Journal of Labelled Compounds & Radiopharmaceuticals (2005), 48(9), 669-681
CODEN: JLCRD4; ISSN: 0362-4803
PB John Wiley & Sons Ltd.
DT Journal
LA English
OS CASREACT 145:145570
GI



I

AB Sumitriptan, a non-selective 5-HT1B/1D agonist is an effective therapeutic agent for the acute treatment of migraine, but it is contraindicated for use in patients with known heart disease. The first Selective Serotonin One F Receptor Agonist (SSOFRA), 5-(4'-fluorobenzamido)-3-(N-methyl-piperidin-4-yl)-1H-indole was demonstrated to be clin. useful in the treatment of migraine. Although it exhibited high affinity for the 5-HT1F receptor as well as high selectivity for the 5-HT1F receptor relative to 5-HT1B and 5-HT1D receptors, it demonstrated appreciable affinity for the 5-HT1A receptor. Subsequently, a program was launched to discover SSOFRA's with improved selectivity over other 5-HT1 receptor subtypes. As a result of these efforts, N-[3-(1-methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]propanamide (I) was found to possess greater than 100-fold

selectivity over 5-HT1A, 5-HT1B and 5-HT1D receptors. Pursuant to a potential clin. investigation of I, its carbon-14-labeled isotopomer has been prepared by a circuitous route from unlabeled I and used in quant. whole-body autoradiog. studies in rats. The results of these efforts are reported herein.

IT 899827-19-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and pharmacokinetics of C14-labeled propanoylamino(methylpiperidinyl)pyrrolopyridine succinate via oxidative cleavage of acetylamino(methylpiperidinyl)indole followed by cyclization reduction, and addition of succinic acid)

RN 899827-19-1 CAPLUS

CN Propanamide, N-[5-(formylamino)-6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:333695 CAPLUS

DN 140:339199

TI Preparation of 1,4-disubstituted piperidine derivatives and their use as 11-βHSD1 inhibitors

IN Barton, Peter John; Jewsbury, Philip John; Pease, Janet Elizabeth

PA Astrazeneca Ab, Swed.; Astrazeneca UK Limited

SO PCT Int. Appl., 144 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004033427	A1	20040422	WO 2003-GB4318	20031007
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2501611	A1	20040422	CA 2003-2501611	20031007
	AU 2003269242	A1	20040504	AU 2003-269242	20031007
	EP 1556349	A1	20050727	EP 2003-751021	20031007
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003015166	A	20050816	BR 2003-15166	20031007
	CN 1723199	A	20060118	CN 2003-80105353	20031007

	JP 2006506451	T	20060223	JP 2005-500993	20031007
	NO 2005001600	A	20050613	NO 2005-1600	20050330
	US 2005256159	A1	20051117	US 2005-529951	20050401
	ZA 2005002752	A	20060222	ZA 2005-2752	20050405
PRAI	GB 2002-23573	A	20021011		
	GB 2003-10446	A	20030507		
	WO 2003-GB4318	W	20031007		

OS MARPAT 140:339199

GI



I

AB The title compds. [I; A = carbocyclyl, heterocyclyl; R1 = halo, NO2, CN, OH, etc.; n = 0-5; X = a bond, CO, SO2, CONR11, CSNR11, C(O)O, C(:NR11), CH2 (wherein R11 = H, alkyl, carbocyclyl, heterocyclyl); Y = H, alkyl, alkenyl, carbocyclyl, etc.; R12 = OH, Me, Et. Pr; m, q = 0-1], useful in the manufacture of a medicament for treating diabetes, obesity, hyperlipidemia, etc., were prepared Thus, reacting (4-chlorophenyl)(4-piperidyl)methanone.HCl with 4-fluorobenzoyl chloride in the presence of Et3N in DCM afforded 29% 1-(4-fluorobenzoyl)-4-(4-chlorobenzoyl)piperidine. The compds. I typically show an IC50 < 10 μM against 11βHSD1. The pharmaceutical composition comprising the compound I is claimed.

IT 681133-44-8P 681134-40-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1,4-disubstituted piperidine derivs. and their use as 11-βHSD1 inhibitors)

RN 681133-44-8 CAPLUS

CN Piperidine, 1-(4-fluorobenzoyl)-4-[(6-methyl-2-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 681134-40-7 CAPLUS

CN Piperidine, 1-[(4-fluorophenyl)sulfonyl]-4-[(6-methyl-2-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:314934 CAPLUS
DN 136:340592
TI Preparation of 4-[4-(piperidin-1-ylcarbonyl)piperidin-1-ylmethyl]pyridin-2-ylamines as antagonists of histamine H3 receptors
IN Aslanian, Robert G.; Shih, Neng-Yang; Ting, Pauline C.; Berlin, Michael Y.; Rosenblum, Stuart B.; McCormick, Kevin D.; Tom, Wing C.; Boyce, Christopher W.; Mangiaracina, Pietro; Mutahi, Mwangi Wa; Piwinski, John J.
PA Schering Corporation, USA
SO PCT Int. Appl., 144 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002032893	A2	20020425	WO 2001-US32151	20011015
	WO 2002032893	A3	20020822		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2424664	A1	20020425	CA 2001-2424664	20011015
	AU 200215355	A	20020429	AU 2002-15355	20011015
	US 2003045519	A1	20030306	US 2001-978267	20011015
	US 6720328	B2	20040413		
	BR 2001014754	A	20030701	BR 2001-14754	20011015
	EP 1326858	A2	20030716	EP 2001-983968	20011015
	EP 1326858	B1	20051214		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	CN 1469873	A	20040121	CN 2001-817512	20011015
	HU 200303835	A2	20040301	HU 2003-3835	20011015
	JP 2004511553	T	20040415	JP 2002-536275	20011015
	NZ 524857	A	20041224	NZ 2001-524857	20011015
	EP 1571145	A1	20050907	EP 2005-9405	20011015
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR				
	AT 312833	T	20051215	AT 2001-983968	20011015
	ES 2250500	T3	20060416	ES 2001-1983968	20011015
	CN 1803795	A	20060719	CN 2005-10131094	20011015
	TW 258474	B	20060721	TW 2001-90125385	20011015
	ZA 2003002521	A	20040630	ZA 2003-2521	20030331
	IN 2003CN00528	A	20050415	IN 2003-CN528	20030411
	NO 2003001744	A	20030614	NO 2003-1744	20030415
	HK 1052935	A1	20060519	HK 2003-105161	20030717
	US 2004097513	A1	20040520	US 2003-699189	20031031
	AU 2006252027	A1	20070111	AU 2006-252027	20061213
PRAI	US 2000-240901P	P	20001017		
	AU 2002-215355	A3	20011015		
	CN 2001-817512	A3	20011015		
	EP 2001-983968	A3	20011015		
	US 2001-978267	A3	20011015		
	WO 2001-US32151	W	20011015		

OS MARPAT 136:340592
GI



I



II

AB The title compds. [I; R1 = (un)substituted aryl, heteroaryl, alkyl, etc.; X = CO, C(NOR3), C(NNR4R5), etc.; M1 = C; M2 = C, N; M3, M4 = C, N; Y = CH2, CO, C(NOH), etc.; Z = alkyl; R2 = (un)substituted 5-6 membered heteroaryl; R3 = H, alkyl, aryl, etc.; R4 = H, alkyl, aryl, etc.; R5 = H, alkyl, COR4, etc.; R12, R13 = alkyl, OH, alkoxy, F; a, b = 0-2; n, p = 1-3, with the proviso that when M3 and M4 are both N atoms, then p = 2 or 3], useful in treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion), were prepared E.g., a multi-step synthesis of II which showed Ki of 0.83 nM in H3 receptor binging assay, was given. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compds. I in combination with a H1 receptor antagonist.

IT 416850-86-7P 416851-23-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-[4-(piperidin-1-ylcarbonyl)piperidin-1-ylmethyl]pyridin-2-ylamines as antagonists of histamine H3 receptors)

RN 416850-86-7 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[(6-methoxy-2-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 416851-23-5 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[(6-methyl-2-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)



L24 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1994:457281 CAPLUS
DN 121:57281
TI Dual antagonists of platelet activating factor and histamine. 2. Pyridine ring substitution of N-acetyl-4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidines
AU Wong, Jesse K.; Piwinski, John J.; Green, Michael J.; Ganguly, Ashit K.; Anthes, John C.; Billah, M. Motasim
CS Dep. Chem. Res., Schering-Plough Res. Inst., Kenilworth, NJ, 07033-0539, USA
SO Bioorganic & Medicinal Chemistry Letters (1993), 3(6), 1073-8
CODEN: BMCLE8; ISSN: 0960-894X
DT Journal
LA English
GI



I

AB A series of pyridine ring substituted 1-acetyl-4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidines (I; X, Z = H, Me, OH, OMe; Y = H, Me, Cl, Ph, OMe, SMe, CHO, CH2OH, Ac, Br), which are antagonists of both PAF and histamine, were prepared by one of three different methods. Analogs with substituents at C-3 were found to be the best dual antagonists among their corresponding regioisomers. Analogs with an electron donating substituent at the C-3 position are generally better antagonists of both PAF and histamine than analogs with electron withdrawing groups.
IT 156073-04-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reactions of, in synthesis of benzocycloheptapyridinylidene piperidines)
RN 156073-04-0 CAPLUS
CN Methanone, [3-[2-(3-chlorophenyl)ethyl]-6-methyl-2-pyridinyl](1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)


Me
N
O
C
N
Me
CH2
CH2
Cl